About Vimentin
Vimentin (VIM) is a protein
from Homo sapiens identified by UniProt accession
P08670, 466 residues long.
MolForge cross-references it against 0 known binders and
1,248 disease associations.
Target properties
| Protein name | Vimentin |
| UniProt accession | P08670 |
| Gene | VIM |
| Organism | Homo sapiens |
| Length | 466 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (1248)
Diseases linked to this target (Open Targets).
- Partial congenital cataract · score 0.46
- Developmental cataract · score 0.43
- pulverulent cataract · score 0.37
- aspartate aminotransferase measurement · score 0.37
- total cholesterol measurement · score 0.35
- high density lipoprotein cholesterol measurement · score 0.32
- low density lipoprotein cholesterol measurement · score 0.30
- glioblastoma multiforme · score 0.29
- hypertension · score 0.27
- head and neck squamous cell carcinoma · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P08670-F1 | alphafold | PREDICTED | 77.09 | — |
Amino-acid sequence (466 residues)
MSTRSVSSSS YRRMFGGPGT ASRPSSSRSY VTTSTRTYSL GSALRPSTSR SLYASSPGGV YATRSSAVRL RSSVPGVRLL QDSVDFSLAD AINTEFKNTR TNEKVELQEL NDRFANYIDK VRFLEQQNKI LLAELEQLKG QGKSRLGDLY EEEMRELRRQ VDQLTNDKAR VEVERDNLAE DIMRLREKLQ EEMLQREEAE NTLQSFRQDV DNASLARLDL ERKVESLQEE IAFLKKLHEE EIQELQAQIQ EQHVQIDVDV SKPDLTAALR DVRQQYESVA AKNLQEAEEW YKSKFADLSE AANRNNDALR QAKQESTEYR RQVQSLTCEV DALKGTNESL ERQMREMEEN FAVEAANYQD TIGRLQDEIQ NMKEEMARHL REYQDLLNVK MALDIEIATY RKLLEGEESR ISLPLPNFSS LNLRETNLDS LPLVDTHSKR TLLIKTVETR DGQVINETSQ HHDDLE
Explore Vimentin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets